Type 1 @entity6 is an intrinsically unstable condition because of the loss of both @entity2690 secretion and @entity413 sensing. Guidelines to treat type 1 @entity6 have become stricter since results from the @entity6 Control and Complications Trial (DCCT) demonstrated the close relationship between @entity455 and HbA1c levels. Therapeutic strategies first require the treatment of underlying organic causes of the brittleness associated with the optimization of @entity2690 therapy including continuous subcutaneous @entity2690 infusion and @entity413 monitoring. Alternative approaches may still be needed for the most severely affected @entity1 . During the last decade, islet transplantation has gone from an inconsistent 1-year rate of @entity2690 independence of 10% to 80% and could reach 50% at 5 years, at the expense of non-negligible side effects. Among potential causes of islet transplantation success, sufficient islet mass and low levels of cellular autoimmunity are of critical importance. The main issues are currently the availability of an unlimited source of @entity2690 -secreting cells, and the immunosuppressive @entity137 . Today, islet alone and islet after kidney transplantation are offered in a limited number of isolation centres, usually in clinical trials. Islet after kidney transplantation can be considered in type 1 @entity6 @entity1 with @entity454 that are ineligible for double kidney-pancreas transplantation. Islet transplantation alone is proposed to C-peptide negative adult @entity6 @entity1 with a body weight <80 kg or low daily @entity2690 needs with creatinine clearance above 60 ml/min, @entity633 lower than 300mg/24H and without desire for pregnancy in @entity1 . Currently and until a more complete assessment of the 5- and probably 10-year overall benefit-risk ratio is available, islet transplantation remains a clinical research procedure.

XXXX cell therapy: a decade later.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['microangiopathy'] @entity137 :: ('MESH:D064420', 'Disease') :: ['drug side effects'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetic', 'diabetes'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage kidney disease']
@entity6 :: (MESH:D003920,Disease) :: ['Diabetes']
